Cite
HARVARD Citation
Pivot, X. et al. (2017). Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study. European journal of cancer. pp. 82-90. [Online].